使用热休克蛋白-肽复合物的自体肾细胞癌疫苗。

Autologous renal cell cancer vaccines using heat shock protein-peptide complexes.

作者信息

Aalamian Maryam, Fuchs Ephraim, Gupta Renu, Levey Daniel L

机构信息

Medical Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Hospital, Baltimore, MD 21231, USA.

出版信息

Urol Oncol. 2006 Sep-Oct;24(5):425-33. doi: 10.1016/j.urolonc.2005.08.009.

DOI:10.1016/j.urolonc.2005.08.009

PMID:16962495

Abstract

Investigations into the role of heat shock proteins (HSPs) in immune response have progressed well into a third decade, and indications of their use for the treatment of renal cell carcinoma (RCC) in the adjuvant setting will be revealed in the near future when a randomized phase III clinical trial is completed. Additional ongoing and planned randomized clinical trials will test the efficacy of HSP-based vaccines in more advanced stages of RCC. This review describes the compelling scientific rationale behind testing HSPs in RCC against the backdrop of other immunotherapeutic approaches in this indication.

摘要

对热休克蛋白（HSPs）在免疫反应中的作用的研究已经顺利进入第三个十年，当一项随机III期临床试验完成时，在辅助治疗中使用它们治疗肾细胞癌（RCC）的迹象将在不久后显现。其他正在进行和计划中的随机临床试验将测试基于HSP的疫苗在RCC更晚期阶段的疗效。本综述描述了在RCC中测试HSPs背后令人信服的科学原理，以该适应症的其他免疫治疗方法为背景。